The Platinum II Study
Research type
Research Study
Full title
Genetic Susceptibility and biomarkers of platinum related toxicities: a longitudinal study
IRAS ID
314120
Contact name
Robert Huddart
Contact email
Sponsor organisation
Melvin & Bren Simon Comprehensive Cancer Centre Indiana University
Duration of Study in the UK
2 years, 0 months, 28 days
Research summary
This study is a continuation of the Platinum I study, which recruited patients treated for a histologically or serologically confirmed testicular germ cell tumour (or extragonadal germ cell tumour) treated with cisplatin chemotherapy. The Platinum I study investigated the long term health of such patients using questionnaires, basic measurements, audiometric testing and blood sampling. The findings helped researchers to understand the long term toxicities associated with cisplatin and identified genetic variations which may be associated with these toxicities. The Platinum II study will continue the longitudinal research started with Platinum I, with the objective of understanding the impact of these toxicities on quality of life, the role of co-morbidities and modifiable risk factors, and the role of genetic variation to identify high risk groups.
REC name
West of Scotland REC 1
REC reference
23/WS/0045
Date of REC Opinion
12 May 2023
REC opinion
Further Information Favourable Opinion